Morse Michael, Langer Lee, Starodub Alexander, Hobeika Amy, Clay Timothy, Lyerly H Kim
Department of Medicine, Duke University Medical Center, 401 MSRB, Research Drive, Durham, NC 27710, USA.
Surg Oncol Clin N Am. 2007 Oct;16(4):873-900, x. doi: 10.1016/j.soc.2007.07.005.
Because chemotherapy is standard in the treatment of colorectal cancer, it is important to demonstrate whether immunizations may be given to patients receiving systemic chemotherapy. Although some studies have demonstrated immune responses in patients with metastatic colorectal carcinoma who failed standard chemotherapy, the setting of minimal residual disease may be the preferred setting for cancer vaccines. It may be important to choose antigens that have functions important to the cancer cell. The best adjuvant is not well established and may depend on the type of immune response desired. The immune system is "programmed" to down-regulate immune responses once they have become activated to avoid the development of autoimmune disease.
由于化疗是结直肠癌治疗的标准方法，因此证明接受全身化疗的患者是否可以接种疫苗很重要。尽管一些研究表明，在标准化疗失败的转移性结直肠癌患者中存在免疫反应，但微小残留病的情况可能是癌症疫苗的首选情况。选择对癌细胞具有重要功能的抗原可能很重要。最佳佐剂尚未完全确定，可能取决于所需的免疫反应类型。一旦免疫系统被激活，就会“编程”下调免疫反应，以避免自身免疫性疾病的发生。
